Back to top

Image: Bigstock

Epizyme, Inc.

Read MoreHide Full Article

With no approved products in its portfolio as of yet, Epizyme relies heavily on its collaborators for revenues. Epizyme’s efforts on developing its lead candidate, tazemetostat, for a number of hematological malignancies and genetically defined solid tumors are impressive. Moreover, the company’s efforts on evaluating tazemetostat, in combination with anti-PD 1 or PDL-1 agent, are also encouraging. The company’s collaboration agreement with Celgene for small-molecule HMT inhibitors including pinometostat is a big positive. However, with no approved product in its kitty, Epizyme is highly dependent on its collaboration partners for top-line growth. Moreover, most of its candidates are in early stages of development and hence are several years away from commercialization. Loss estimates have widened lately ahead of the Q1 earnings results. Epizyme has a negative record of earnings surprises in recent quarters.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Epizyme, Inc. (EPZM) - free report >>

Published in